Name: Lirafugratinib (Lyrfigtu) in Previously treated FGFR2 fusion or rearrangement-positive cholangiocarcinoma: Average sales price and wholesale acquisition cost
Published: 2026-09-27T09:44:05-04:00

Product information and disease description Product description Product information

Average sales price and wholesale acquisition cost

2 evidence topics · 3 sources

Wholesale acquisition cost and average sales price of lirafugratinib

No evidence found.

Commercial status bearing on the absence of a published price

“Lyrfigtu is expected to be available to patients in the U.S. by Q4 2026.” (opens the source at this quote in a new tab)

“NOW APPROVED! Available Soon” (opens the source at this quote in a new tab)

Average monthly United States price of futibatinib, an approved comparator

“The cost of drugs was obtained from www.pharmacychecker.com using the FDA label to determine the dosage and number of tablets required per day. This methodology excludes any private or governmental insurance coverage, which would cover the entire cost or more likely a fraction of the stated price.” (opens the source at this quote in a new tab)
“The average monthly cost for the treatment of neoplastic diseases was $17,900 with a price of $44,000 for futibatinib (used to treat cholangiocarcinomas with FGFR2 fusions) and minimum of $5100 for binimetinib (melanoma).” (opens the source at this quote in a new tab)
“We retrieved drug prices in November 2023 from www.pharmacychecker.com for the average patient living in the state of North Carolina (ZIP code 28791). These values represent the retail price of a drug at the pharmacy as determined by negotiations between pharmacies and insurers and reflect both wholesale and retail markups.” (opens the source at this quote in a new tab)